Published in Clin Infect Dis on January 20, 2006
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62
Health disparities and the criminal justice system: an agenda for further research and action. J Urban Health (2012) 1.54
Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis (2011) 1.13
Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J Infect Dis (2012) 1.08
Perceptions of drug users regarding hepatitis C screening and care: a qualitative study. Harm Reduct J (2013) 1.01
Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS One (2009) 1.00
Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med (2010) 0.97
Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. Am J Public Health (2009) 0.96
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med (2014) 0.96
Hepatitis C screening: getting it right. Hepatology (2012) 0.94
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. Drug Alcohol Depend (2009) 0.93
Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia (2011) 0.88
Managing chronic hepatitis C in primary-care settings: more than antiviral therapy. Public Health Rep (2007) 0.87
Hepatitis C screening trends in a large integrated health system. Am J Med (2014) 0.86
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. Eur J Clin Microbiol Infect Dis (2015) 0.84
Managing Hepatitis C in Users of Illicit Drugs. Curr Hepat Rep (2007) 0.82
Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. J Addict Med (2014) 0.81
The beginning of a new era in understanding hepatitis C virus prevention. J Infect Dis (2010) 0.80
Low rates of hepatitis A and B vaccination in patients with chronic hepatitis C at an urban methadone maintenance program. J Addict Dis (2010) 0.78
Organ system view of the hepatic innate immunity in HCV infection. J Med Virol (2016) 0.78
Retinoid regulation of antiviral innate immunity in hepatocytes. Hepatology (2016) 0.76
Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol. BMC Infect Dis (2015) 0.75
Risk Behaviors Among Suburban Women who Use Methamphetamine: Social Harms and Social Solutions. J Appl Soc Sci (Boulder) (2015) 0.75
Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs. J Prim Prev (2017) 0.75
Gender-based differences in injecting drug use by young adults who experienced maltreatment in childhood: Findings from an Australian birth cohort study. Drug Alcohol Depend (2017) 0.75
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health (2002) 8.17
NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements (2004) 5.19
Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health (2001) 4.57
Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med (2003) 4.30
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology (2000) 3.53
Prevention of spread of hepatitis C. Hepatology (2002) 2.90
Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol (2006) 2.47
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med (2001) 2.12
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ (2004) 2.03
Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health (2001) 2.02
Prevention and treatment of hepatitis C in injection drug users. Hepatology (2002) 1.88
Treatment of hepatitis C infection in injection drug users. Hepatology (2001) 1.87
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology (2003) 1.86
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80
A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology (2004) 1.52
Management of hepatitis C. NIH Consens Statement (1998) 1.44
Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis (2005) 1.41
Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health (2002) 1.40
Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol (2003) 1.39
Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis (2006) 1.23
The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat (2005) 1.22
Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis (2005) 1.18
Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis (2005) 1.10
Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis (2005) 1.09
Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis (2005) 1.09
Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol (2004) 1.05
Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis (2005) 1.04
Liver transplantation and opioid dependence. JAMA (2001) 1.00
Managing chronic hepatitis C acquired through intravenous drug use. QJM (2001) 0.99
Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol (2004) 0.96
Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther (2002) 0.92
Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis (2005) 0.89
A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis (2005) 0.85
Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg (2005) 0.82
Ethical issues in the treatment of hepatitis C. Clin Gastroenterol Hepatol (2005) 0.80
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health (2005) 2.56
A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend (2003) 1.99
Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health (2003) 1.97
Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health (2003) 1.96
Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol (2003) 1.82
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80
HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health (2005) 1.77
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Reinterpreting ethnic patterns among white and African American men who inject heroin: a social science of medicine approach. PLoS Med (2006) 1.62
Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis (2003) 1.62
Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2004) 1.46
HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir Immune Defic Syndr (2006) 1.44
Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis. J Urban Health (2007) 1.41
Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology (2007) 1.40
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 1.30
HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology (2012) 1.30
Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS (2003) 1.28
Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis (2012) 1.24
Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis (2013) 1.18
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol (2011) 1.18
Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol (2004) 1.15
Secondary syringe exchange among injection drug users. J Urban Health (2003) 1.12
Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis (2004) 1.10
IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis (2011) 1.07
What's community got to do with it? Implementation models of syringe exchange programs. AIDS Educ Prev (2005) 1.02
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol (2005) 1.02
Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis (2007) 1.00
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2004) 0.95
MBL2 and hepatitis C virus infection among injection drug users. BMC Infect Dis (2008) 0.86
Pandemic influenza: implications for programs controlling for HIV infection, tuberculosis, and chronic viral hepatitis. Am J Public Health (2009) 0.85
More rare birds, and the occasional swan. Gastroenterology (2009) 0.83
Managing Hepatitis C in Users of Illicit Drugs. Curr Hepat Rep (2007) 0.82
Prevalence of SEN viruses among injection drug users in the San Francisco Bay area. J Infect Dis (2003) 0.81
Persistent HIV incidence among injection drug users in San Francisco during the 1990s: results of five studies. J Acquir Immune Defic Syndr (2004) 0.80
Value of expanding HCV screening and treatment policies in the United States. Am J Manag Care (2016) 0.80
HCV infection clearance with functional or non-functional caspase-12. Scand J Gastroenterol (2007) 0.79
Racial/ethnic differences in spontaneous HCV clearance in HIV infected and uninfected women. Dig Dis Sci (2012) 0.79
Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. Liver Int (2004) 0.78
Written in response to Scott LD: treating hepatitis C in active injection drug users. Am J Gastroenterol (2005) 0.75
PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. J Med Virol (2004) 0.75
Transforming strategies to provide access to care. J Fam Pract (2010) 0.75
The risk of emergency room treatment due to overdose in injection drug users. J Addict Dis (2009) 0.75